Rhumbline Advisers Janux Therapeutics, Inc. Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 59,391 shares of JANX stock, worth $1.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

59,391

Previous 42,650 39.25%

Holding current value

$1.35 Million

Previous $1.15 Million 19.11%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$22.62 - $33.2 $378,681 - $555,801	16,741 Added 39.25%	59,391 $1.37 Million
Q1 2025 Apr 08, 2025	BUY	$27.0 - $57.81 $121,419 - $259,971	4,497 Added 11.79%	42,650 $1.24 Million
Q4 2024 May 29, 2025	SELL	$40.18 - $66.83 $180,689 - $300,534	-4,497 Reduced 10.54%	38,153 $2.04 Million
Q4 2024 Jan 30, 2025	BUY	$40.18 - $66.83 $24,067 - $40,031	599 Added 1.6%	38,153 $2.04 Million
Q3 2024 Nov 12, 2024	SELL	$35.29 - $50.26 $16,021 - $22,818	-454 Reduced 1.19%	37,554 $1.71 Million
Q2 2024 Aug 01, 2024	BUY	$35.12 - $64.78 $389,305 - $718,086	11,085 Added 41.17%	38,008 $1.59 Million
Q1 2024 May 09, 2024	BUY	$7.93 - $49.75 $6,645 - $41,690	838 Added 3.21%	26,923 $1.01 Million
Q4 2023 Feb 08, 2024	SELL	$5.85 - $11.7 $2,614 - $5,229	-447 Reduced 1.68%	26,085 $279,000
Q3 2023 Nov 09, 2023	SELL	$9.56 - $14.0 $2,351 - $3,444	-246 Reduced 0.92%	26,532 $267,000
Q2 2023 Aug 08, 2023	SELL	$11.08 - $15.92 $786 - $1,130	-71 Reduced 0.26%	26,778 $317,000
Q1 2023 May 11, 2023	BUY	$11.25 - $22.21 $13,027 - $25,719	1,158 Added 4.51%	26,849 $325,000
Q4 2022 Feb 14, 2023	BUY	$11.1 - $18.26 $1,232 - $2,026	111 Added 0.43%	25,691 $338,000
Q3 2022 Nov 10, 2022	BUY	$10.82 - $16.84 $18,155 - $28,257	1,678 Added 7.02%	25,580 $346,000
Q2 2022 Aug 11, 2022	BUY	$9.52 - $15.65 $73,170 - $120,285	7,686 Added 47.4%	23,902 $292,000
Q1 2022 May 12, 2022	BUY	$13.24 - $20.24 $68,569 - $104,822	5,179 Added 46.92%	16,216 $233,000
Q4 2021 Feb 10, 2022	SELL	$15.44 - $27.32 $1,127 - $1,994	-73 Reduced 0.66%	11,037 $218,000
Q3 2021 Nov 12, 2021	BUY	$20.7 - $34.69 $229,977 - $385,405	11,110 New	11,110 $240,000

Others Institutions Holding JANX

# of Institutions

186

Shares Held

55.9M

Call Options Held

869K

Put Options Held

652K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $945M
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Janux Therapeutics, Inc. Transaction History